


For newly diagnosed adults with Ph+ CML in CP

ACHIEVE MILESTONES THAT MATTER

More patients achieved MMR* at Year 1 and Year 5 vs imatinib¹

SPRYCEL
dasatinib 100 mg tablets



*MMR (at any time) was defined as BCR-ABL ratios of $\leq 0.1\%$ by RQ-PCR in peripheral blood samples standardized on the International scale. These are cumulative rates representing minimum follow-up for the timeframe specified.¹

¹Inclusive of cCCyR in newly diagnosed adult patients with CP Ph+ CML by 1 and 5 years.¹

²cCCyR was defined as CCyR (0% Ph+ metaphases) on 2 consecutive occasions, at least 28 days apart.¹

³Adjusted for Hasford score and indicated statistical significance at a predefined nominal level of significance.¹

Achieving MMR early is an important treatment milestone^{2,3}

cCCyR^{†‡} rates vs imatinib by Year 1 and Year 5:

- **YEAR 1 cCCyR:** 77% (95% CI: 71%–82%) for SPRYCEL (n=259) vs 66% (95% CI: 60%–72%) for imatinib (n=260; $P=0.007^{\S}$)¹
- **YEAR 5 cCCyR:** 83% for SPRYCEL (n=259) vs 79% for imatinib (n=260)¹

Dasatinib does not appear to be active against the T315I mutation, based on *in vitro* data.¹

DASISION study design: Phase III, open-label, randomized study of SPRYCEL 100 mg once daily (n=259) vs imatinib 400 mg once daily (n=260) in adults with newly diagnosed CP Ph+ CML (n=519). The primary endpoint was the rate of cCCyR[‡] within 12 months. Select secondary endpoints included MMR* at any time.^{1,4}

cCCyR=confirmed complete cytogenetic response; CI=confidence interval; CP=chronic phase; MMR=major molecular response; RQ-PCR=real-time quantitative polymerase chain reaction; TKI=tyrosine kinase inhibitor.

INDICATION

SPRYCEL® (dasatinib) is indicated for the treatment of adult patients with:

- Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase

SELECT IMPORTANT SAFETY INFORMATION

SPRYCEL is associated with the following warnings and precautions: myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, and embryo-fetal toxicity.

- In newly diagnosed chronic phase CML patients:
 - Drug-related serious adverse reactions (SARs) were reported for 16.7% of SPRYCEL-treated patients. Serious adverse reactions reported in $\geq 5\%$ of patients included pleural effusion (5%)
 - The most common adverse reactions ($\geq 15\%$) included myelosuppression, fluid retention, and diarrhea

Please see detailed Important Safety Information throughout this brochure and full **Prescribing Information**.

NO NEW TRANSFORMATIONS IN PATIENTS WHO RECEIVED SPRYCEL AFTER YEAR 3, THROUGH YEAR 5⁵

97% of SPRYCEL patients remained in Chronic Phase through Year 5^{1*}

Patients transformed by Year while on study⁵

	Year 1	Year 2	Year 3	Year 4	Year 5
SPRYCEL	5	1	2	0	0
imatinib	9	4	0	1	1

3% Transformed
(8/259)

6% Transformed
(15/260)

94% of imatinib patients remained in chronic phase while on study.¹

*A minimum of 5 years of follow-up. All randomized patients who transformed while on study progressed to either accelerated phase or blast crisis.⁵

SPRYCEL IS THE ONLY FIRST-LINE TKI WITH ONCE-DAILY DOSING AND NO MEAL RESTRICTIONS



ONE
Pill



ONCE
Daily



WITH OR WITHOUT
Food



- Taken either in the morning or evening; no fasting requirements¹
- Tablets should not be crushed, cut, or chewed; they should be swallowed whole¹
- In clinical studies, treatment with SPRYCEL was continued until disease progression or until no longer tolerated by the patient¹

IMPORTANT SAFETY INFORMATION

Drug Interactions:

Effect of Other Drugs on Dasatinib

- **Strong CYP3A4 inhibitors:** The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a SPRYCEL dose reduction — **Grapefruit juice** may increase plasma concentrations of SPRYCEL and should be avoided
- **Strong CYP3A4 inducers:** The coadministration of SPRYCEL with strong CYP3A inducers may decrease dasatinib concentrations. Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a SPRYCEL dose increase — **St. John's Wort** may decrease plasma concentrations of SPRYCEL and should be avoided
- **Gastric Acid Reducing Agents:** The coadministration of SPRYCEL with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy

Do not administer H₂ antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H₂ antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. Avoid simultaneous administration of SPRYCEL with antacids.

SPRYCEL
dasatinib 100 mg
tablets

Please see detailed Important Safety Information throughout this brochure and full [Prescribing Information](#).

IMPORTANT SAFETY INFORMATION (cont'd)

Myelosuppression:

Treatment with SPRYCEL is associated with severe (NCI CTCAE Grade 3/4) thrombocytopenia, neutropenia, and anemia, which occur earlier and more frequently in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML. Myelosuppression was reported in patients with normal baseline laboratory values as well as in patients with pre-existing laboratory abnormalities.

- In patients with chronic phase CML, perform complete blood counts (CBCs) every 2 weeks for 12 weeks, then every 3 months thereafter, or as clinically indicated
- Myelosuppression is generally reversible and usually managed by withholding SPRYCEL temporarily and/or dose reduction
 - In clinical studies, myelosuppression may have also been managed by discontinuation of study therapy
 - Hematopoietic growth factor has been used in patients with resistant myelosuppression

Bleeding-Related Events:

SPRYCEL can cause serious and fatal bleeding. In all CML or Ph+ ALL clinical studies, Grade ≥ 3 central nervous system (CNS) hemorrhages, including fatalities, occurred in <1% of patients receiving SPRYCEL. The incidence of Grade 3/4 hemorrhage occurred in 5.8% of patients and generally required treatment interruptions and transfusions. The incidence of Grade 5 hemorrhage occurred in 0.4% of patients. The most frequent site of hemorrhage was gastrointestinal.

- Most bleeding events in clinical studies were associated with severe thrombocytopenia
- In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction *in vitro*
- Concomitant medications that inhibit platelet function or anticoagulants may increase the risk of hemorrhage

Fluid Retention:

SPRYCEL may cause fluid retention. After 5 years of follow-up in the randomized newly diagnosed chronic phase CML study (n=258), grade 3/4 fluid retention was reported in 5% of patients, including 3% of patients with grade 3/4 pleural effusion. In patients with newly diagnosed or imatinib-resistant or -intolerant chronic phase CML, grade 3/4 fluid retention occurred in 6% of patients treated with SPRYCEL at the recommended dose (n=548).

- Patients who develop symptoms of pleural effusion or other fluid retention, such as new or worsened dyspnea on exertion or at rest, pleuritic chest pain, or dry cough should be evaluated promptly with a chest x-ray or additional diagnostic imaging as appropriate
- Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids
- Severe pleural effusion may require thoracentesis and oxygen therapy
- Consider dose reduction or treatment interruption

Cardiovascular Toxicity:

SPRYCEL can cause cardiac dysfunction. After 5 years of follow-up in the randomized, newly diagnosed chronic phase CML trial (n=258), the following cardiac adverse reactions occurred:

- Cardiac ischemic events (3.9% dasatinib vs 1.6% imatinib), cardiac-related fluid retention (8.5% dasatinib vs 3.9% imatinib), and conduction system abnormalities, most commonly arrhythmia and palpitations (7.0% dasatinib vs 5.0% imatinib). Two cases (0.8%) of peripheral arterial occlusive disease occurred with imatinib and 2 (0.8%) transient ischemic attacks occurred with dasatinib

Monitor patients for signs or symptoms consistent with cardiac dysfunction and treat appropriately.

Pulmonary Arterial Hypertension (PAH):

SPRYCEL may increase the risk of developing PAH, which may occur any time after initiation, including after more than 1 year of treatment. Manifestations include dyspnea, fatigue, hypoxia, and fluid retention. PAH may be reversible on discontinuation of SPRYCEL.

- Evaluate patients for signs and symptoms of underlying cardiopulmonary disease prior to initiating SPRYCEL and during treatment. If PAH is confirmed, SPRYCEL should be permanently discontinued

QT Prolongation:

SPRYCEL may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy.

- Correct hypokalemia or hypomagnesemia prior to and during SPRYCEL administration

SPRYCEL
dasatinib 100 mg tablets

IMPORTANT SAFETY INFORMATION (cont'd)

Severe Dermatologic Reactions:

Cases of severe mucocutaneous dermatologic reactions, including Stevens-Johnson syndrome and erythema multiforme, have been reported in patients treated with SPRYCEL.

- Discontinue permanently in patients who experience a severe mucocutaneous reaction during treatment if no other etiology can be identified

Tumor Lysis Syndrome (TLS):

TLS has been reported in patients with resistance to prior imatinib therapy, primarily in advanced phase disease.

- Due to potential for TLS, maintain adequate hydration, correct uric acid levels prior to initiating therapy with SPRYCEL, and monitor electrolyte levels
- Patients with advanced stage disease and/or high tumor burden may be at increased risk and should be monitored more frequently

Embryo-Fetal Toxicity:

Based on limited human data, SPRYCEL can cause fetal harm when administered to a pregnant woman. Hydrops fetalis, fetal leukopenia and fetal thrombocytopenia have been reported with maternal exposure to SPRYCEL. Transplacental transfer of dasatinib has been measured in fetal plasma and amniotic fluid at concentrations comparable to those in maternal plasma.

- Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with SPRYCEL and for 30 days after the last dose

Lactation:

No data are available regarding the presence of dasatinib in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. However, dasatinib is present in the milk of lactating rats.

- Because of the potential for serious adverse reactions in nursing children from SPRYCEL, breastfeeding is not recommended during treatment with SPRYCEL and for 2 weeks after the last dose

Drug Interactions:

Effect of Other Drugs on Dasatinib

- **Strong CYP3A4 inhibitors:** The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a SPRYCEL dose reduction
 - **Grapefruit juice** may increase plasma concentrations of SPRYCEL and should be avoided
- **Strong CYP3A4 inducers:** The coadministration of SPRYCEL with strong CYP3A inducers may decrease dasatinib concentrations. Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a SPRYCEL dose increase
 - **St. John's wort** may decrease plasma concentrations of SPRYCEL and should be avoided
- **Gastric Acid Reducing Agents:** The coadministration of SPRYCEL with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy

Do not administer H₂ antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H₂ antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. Avoid simultaneous administration of SPRYCEL with antacids.

Adverse Reactions:

The safety data reflects exposure to SPRYCEL at doses tested in clinical studies (n=2712) including 324 patients with newly diagnosed chronic phase CML and 2388 adult patients with imatinib-resistant or -intolerant chronic or advanced phase Ph+ CML or Ph+ ALL.

The median duration of therapy in a total of 2712 SPRYCEL-treated patients was 19.2 months (range 0–93.2 months). Median duration of therapy in:

- 1618 patients with chronic phase CML was 29 months (range 0–92.9 months)
 - Median duration for 324 patients in the newly diagnosed chronic phase CML trial was approximately 60 months

In the newly diagnosed chronic phase CML trial, after a minimum of 60 months of follow-up, the cumulative discontinuation rate for 258 patients was 39%.

In the overall population of 2712 SPRYCEL-treated patients, 88% of patients experienced adverse reactions at some time and 19% experienced adverse reactions leading to treatment discontinuation.

Among the 1618 SPRYCEL-treated patients with chronic phase CML, drug-related adverse reactions leading to discontinuation were reported in 329 (20.3%) patients.

- In the newly diagnosed chronic phase CML trial, drug was discontinued for adverse reactions in 16% of SPRYCEL-treated patients with a minimum of 60 months of follow-up

SPRYCEL
dasatinib 100 mg
tablets

IMPORTANT SAFETY INFORMATION (cont'd)

Patients ≥ 65 years are more likely to experience the commonly reported adverse reactions of fatigue, pleural effusion, diarrhea, dyspnea, cough, lower gastrointestinal hemorrhage, and appetite disturbance, and more likely to experience the less frequently reported adverse reactions of abdominal distention, dizziness, pericardial effusion, congestive heart failure, hypertension, pulmonary edema and weight decrease, and should be monitored closely.

- In newly diagnosed chronic phase CML patients:
 - Drug-related serious adverse reactions (SARs) were reported for 16.7% of SPRYCEL-treated patients. Serious adverse reactions reported in $\geq 5\%$ of patients included pleural effusion (5%)
 - The most common adverse reactions ($\geq 15\%$) included myelosuppression, fluid retention, and diarrhea
 - Grade 3/4 laboratory abnormalities included neutropenia (29%), thrombocytopenia (22%), anemia (13%), hypophosphatemia (7%), hypocalcemia (4%), elevated bilirubin (1%), and elevated creatinine (1%)
- Grade 3/4 elevations of transaminases or bilirubin and Grade 3/4 hypocalcemia, hypokalemia, and hypophosphatemia were reported in patients with all phases of CML
 - Elevations in transaminases or bilirubin were usually managed with dose reduction or interruption
 - Patients developing Grade 3/4 hypocalcemia during the course of SPRYCEL therapy often had recovery with oral calcium supplementation

Please see full **Prescribing Information**.

References: **1.** SPRYCEL [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2018. **2.** Cortes J, Quintas-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. *Cancer*. 2011;117(6):1113-1122. **3.** NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia.V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed July 12, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. **4.** Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*. 2010;362(24):2260-2270. **5.** Data on file. SPRY 061. Bristol-Myers Squibb Company; 2016.

